EMAIL THIS PAGE TO A FRIEND

Neuropharmacology

Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.


PMID 24863045

Abstract

The immunomodulatory FTY720 (fingolimod) is presently approved for the treatment of relapsing-remitting multiple sclerosis. It is a prodrug that acts by modulating sphingosine 1-phosphate (S1P) receptor signaling. In this study, we have developed and characterized two novel oxazolo-oxazole derivatives of FTY720, ST-968 and the oxy analog ST-1071, which require no preceding activating phosphorylation, and proved to be active in intact cells and triggered S1P1 and S1P3, but not S1P2, receptor internalization as a result of receptor activation. Functionally, ST-968 and ST-1071 acted similar to FTY720 to abrogate S1P-triggered chemotaxis of mouse splenocytes, mouse T cells and human U937xa0cells, and reduced TNFa- and LPS-stimulated endothelial cell permeability. The compounds also reduced TNFα-induced ICAM-1 and VCAM-1 mRNA expression, but restored TNFα-mediated downregulation of PECAM-1 mRNA expression. In an inxa0vivo setting, the application of ST-968 or ST-1071 to mice resulted in a reduction of blood lymphocytes and significantly reduced the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice comparable to FTY720 either by prophylactic or therapeutic treatment. In parallel to the reduced clinical symptoms, infiltration of immune cells in the brain was strongly reduced, and in isolated tissues of brain and spinal cord, the mRNA and protein expressions of ICAM-1 and VCAM-1, as well as of matrix metalloproteinase-9 were reduced by all compounds, whereas PECAM-1 and tissue inhibitor of metalloproteinase TIMP-1 were upregulated. In summary, the data suggest that these novel butterfly derivatives of FTY720 could have considerable implication for future therapies of multiple sclerosis and other autoimmune diseases.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4300383
Anti-ICAM1 (Ab-512) antibody produced in rabbit, affinity isolated antibody
SAB2502120
Anti-ICAM1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405977
Anti-ICAM1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA002126
Anti-ICAM1 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA004877
Anti-ICAM1 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2501702
Anti-TIMP1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1409739
Anti-TIMP1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4502971
Anti-TIMP1 antibody produced in rabbit, affinity isolated antibody
SAB1411349
Anti-TIMP1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB4700326 Monoclonal Anti-CD54 antibody produced in mouse, clone MEM-112, purified immunoglobulin, buffered aqueous solution
SAB4700327
Monoclonal Anti-CD54 antibody produced in mouse, clone MEM-111, purified immunoglobulin, buffered aqueous solution
SAB4700571 Monoclonal Anti-CD54 antibody produced in rat, clone YN1/1.7.4, purified immunoglobulin, buffered aqueous solution
WH0003383M1
Monoclonal Anti-ICAM1 antibody produced in mouse, clone 3H8-2G6, purified immunoglobulin, buffered aqueous solution
WH0007076M1
Monoclonal Anti-TIMP1 antibody produced in mouse, clone 4D12, purified immunoglobulin, buffered aqueous solution
SAB1404470 Monoclonal Anti-TIMP1 antibody produced in mouse, clone 4E7, purified immunoglobulin, buffered aqueous solution